Cover Image
市場調查報告書

癌症骨轉移:開發中產品分析

Bone Metastasis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 251586
出版日期 內容資訊 英文 100 Pages
訂單完成後即時交付
價格
Back to Top
癌症骨轉移:開發中產品分析 Bone Metastasis - Pipeline Review, H1 2017
出版日期: 2017年05月16日 內容資訊: 英文 100 Pages
簡介

所謂癌症骨轉移是指癌細胞由原生部位轉移到骨頭,有骨頭疼痛、骨折、大小便失禁、腳無力等症狀。乳癌、前列腺癌、肺癌、甲狀腺癌、腎臟癌等特定癌症等是致病原因,治療方法有化療、手術、放射治療等。

本報告涵括全球癌症骨轉移治療藥的開發平台,提供目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中產品評估等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

癌症骨轉移概要

治療藥的開發

  • 癌症骨轉移開發中產品:概要
  • 各企業的開發中產品
  • 各大學/研究機關的開發中產品
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

癌症骨轉移:開發治療藥的企業

  • Ablynx NV
  • Amgen Inc
  • Amura Holdings Ltd
  • BiologicsMD Inc
  • ChemoCentryx Inc
  • Deciphera Pharmaceuticals LLC
  • Eli Lilly and Company
  • Leadiant Biosciences Inc
  • Lupin Ltd
  • Mirati Therapeutics Inc
  • Oncobiologics Inc
  • Oncodrone BV
  • OPKO Health Inc
  • Osteologix Holdings Plc
  • R Pharm
  • Redx Pharma Plc
  • 大鵬藥品工業
  • Terpenoid Therapeutics Inc

藥物簡介

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 關注的新聞·新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9277IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Metastasis - Pipeline Review, H1 2017, provides an overview of the Bone Metastasis (Oncology) pipeline landscape.

Bone metastasis occurs when cancer cells spread from their original site to a bone. Signs and symptoms of bone metastasis include bone pain, broken bones, urinary incontinence, bowel incontinence and weakness in the legs. The predisposing factors include certain kinds of cancer (breast, prostate, lung, thyroid, and kidney cancers). Treatment options for bone metastasis are chemotherapy, surgery and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bone Metastasis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Bone Metastasis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Metastasis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bone Metastasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 3, 17 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.

Bone Metastasis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Metastasis (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Bone Metastasis (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bone Metastasis (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bone Metastasis (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bone Metastasis (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bone Metastasis (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bone Metastasis (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bone Metastasis - Overview
    • Bone Metastasis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Bone Metastasis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Bone Metastasis - Companies Involved in Therapeutics Development
    • Ablynx NV
    • Amgen Inc
    • Amura Holdings Ltd
    • BiologicsMD Inc
    • ChemoCentryx Inc
    • Deciphera Pharmaceuticals LLC
    • Eli Lilly and Company
    • Leadiant Biosciences Inc
    • Lupin Ltd
    • Mirati Therapeutics Inc
    • Oncobiologics Inc
    • Oncodrone BV
    • OPKO Health Inc
    • Osteologix Holdings Plc
    • R Pharm
    • Redx Pharma Plc
    • Taiho Pharmaceutical Co Ltd
    • Terpenoid Therapeutics Inc
  • Bone Metastasis - Drug Profiles
    • ADM-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALX-0141 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AM-3701 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AMG-161 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BKM-1644 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BKM-1740 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMD-3151 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • calcifediol ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-354 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DCC-3014 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • denosumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • denosumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • denosumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Inhibit CXCL5 for Bone Metastasis and Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • emibetuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LG-1980 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit SVEP1 for Bone Metastasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NBS-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OCD-155 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Bone Metastasis and Non-Small Cell Lung Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • roneparstat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RPH-203 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RSF-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RSF-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sitravatinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit cFMS Kinase for Immunology and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit GGDPS for Bone Metastasis and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAS-115 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TPH-9 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vicrostatin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Bone Metastasis - Dormant Projects
  • Bone Metastasis - Discontinued Products
  • Bone Metastasis - Product Development Milestones
    • Featured News & Press Releases
      • Jul 06, 2015: R-Pharm Group of Companies Develops Original drug for Treatment of Metastatic Bone Disease
      • May 24, 2011: Daiichi Sankyo and AstraZeneca Announce a Co-Promotion Agreement in Japan for Denosumab, a Treatment of Bone Disorders stemming from Bone Metastasis
      • May 18, 2011: Amgen To Present XGEVA Data At ASCO Annual Meeting
      • Dec 10, 2010: Amgen Presents New XGEVA Breast Cancer Skeletal-Related Event Prevention Data At SABCS
      • Nov 18, 2010: Amgen Receives FDA Approval For XGEVA For Prevention Of Skeletal-Related Events In Patients With Bone Metastases From Solid Tumors
      • Nov 08, 2010: Amgen Announces Phase III Study Results Of Denosumab In Breast Cancer Patients With Bone Metastases
      • Nov 08, 2010: Published Results Show Denosumab Superior to Zometa in Delaying or Preventing Bone Complications in Patients With Bone Metastases From Advanced Breast Cancer
      • Oct 11, 2010: Amgen Reports Integrated Analysis Demonstrates That Denosumab Delays Onset Of Bone Complications Compared To Zometa
      • Jul 17, 2010: Amgen Receives FDA's Priority Review Designation For Denosumab BLA For Reduction Of Skeletal Related Events In Advanced Cancer Patients
      • May 14, 2010: Amgen Submits Denosumab BLA To FDA For Reduction Of Skeletal Related Events In Cancer Patients
      • Aug 03, 2009: Amgen Announces Positive Top-Line Results For Denosumab In Bone Metastases Patients Compared To Zometa
      • Jun 04, 2006: Amgen Announces Phase 2 Interim Data Of Denosumab In Advanced Cancer Patients With Bone Metastases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Bone Metastasis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Bone Metastasis - Pipeline by Ablynx NV, H1 2017
  • Bone Metastasis - Pipeline by Amgen Inc, H1 2017
  • Bone Metastasis - Pipeline by Amura Holdings Ltd, H1 2017
  • Bone Metastasis - Pipeline by BiologicsMD Inc, H1 2017
  • Bone Metastasis - Pipeline by ChemoCentryx Inc, H1 2017
  • Bone Metastasis - Pipeline by Deciphera Pharmaceuticals LLC, H1 2017
  • Bone Metastasis - Pipeline by Eli Lilly and Company, H1 2017
  • Bone Metastasis - Pipeline by Leadiant Biosciences Inc, H1 2017
  • Bone Metastasis - Pipeline by Lupin Ltd, H1 2017
  • Bone Metastasis - Pipeline by Mirati Therapeutics Inc, H1 2017
  • Bone Metastasis - Pipeline by Oncobiologics Inc, H1 2017
  • Bone Metastasis - Pipeline by Oncodrone BV, H1 2017
  • Bone Metastasis - Pipeline by OPKO Health Inc, H1 2017
  • Bone Metastasis - Pipeline by Osteologix Holdings Plc, H1 2017
  • Bone Metastasis - Pipeline by R Pharm, H1 2017
  • Bone Metastasis - Pipeline by Redx Pharma Plc, H1 2017
  • Bone Metastasis - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017
  • Bone Metastasis - Pipeline by Terpenoid Therapeutics Inc, H1 2017
  • Bone Metastasis - Dormant Projects, H1 2017
  • Bone Metastasis - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Bone Metastasis - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Bone Metastasis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top